| [1] |
CHESON B D, FISHER R I, BARRINGTON S F, et al. Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification[J]. J Clin Oncol, 2014, 32(27):3059-3068.
|
| [2] |
OGAMI A, MORIMOTO A, HIBI S, et al. Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child[J]. J Pediatr Hematol Oncol, 2004, 26(7):427-430.
|
| [3] |
GLASER S L, JARRETT R F. The epidemiology of Hodgkin's disease[J]. Baillieres Clin Haematol, 1996, 9(3):401-416.
|
| [4] |
GREEN M R, MONTI S, RODIG S J, et al. Integrative analysis reveals selective 9p24.1 amplification,increased PD-1 ligand expression,and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma[J]. Blood, 2010, 116(17):3268-3277.
|
| [5] |
OLIVEIRA L O D, COSTA I B, QUARESMA J A S. Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development[J]. Rev Med Virol, 2024, 34(4):e2561.
|
| [6] |
SMITH S M, LE BEAU M M, HUO D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia:the University of Chicago series[J]. Blood, 2003, 102(1):43-52.
|
| [7] |
SWERDLOW A J, HIGGINS C D, SMITH P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma:a collaborative British cohort study[J]. J Clin Oncol, 2011, 29(31):4096-4104.
|
| [8] |
SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390.
|
| [9] |
LENZ G, WRIGHT G W, EMRE N C, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways[J]. Proc Natl Acad Sci U S A, 2008, 105(36):13520-13525.
|
| [10] |
COIFFIER B, LEPAGE E, BRIERE J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(4):235-242.
|
| [11] |
PFREUNDSCHUH M, TRÜMPER L, OSTERBORG A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT) Group[J]. Lancet Oncol, 2006, 7(5):379-391.
|
| [12] |
WONG T N, MILLER C A, KLCO J M, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML[J]. Blood, 2016, 127(7):893-897.
|
| [13] |
LARSON R A. Therapy-related myeloid neoplasms[J]. Haematologica, 2009, 94(4):454-459.
|
| [14] |
MISTRY A R, PEDERSEN E W, SOLOMON E, et al. The molecular pathogenesis of acute promyelocytic leukaemia:implications for the clinical management of the disease[J]. Blood Rev, 2003, 17(2):71-97.
|
| [15] |
LEONE G, MELE L, PULSONI A, et al. The incidence of secondary leukemias[J]. Haematologica, 1999, 84(10):937-945.
|
| [16] |
VENUGOPAL S, DEZERN A E. Therapy-related myelodysplastic syndromes and acute myeloid leukemia[J]. Semin Hematol, 2024, 61(6):379-384.
|
| [17] |
MCBRIDE A, WESTERVELT P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies[J]. J Hematol Oncol, 2012, 5:75.
|
| [18] |
MORTON L M, DORES G M, TUCKER M A, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States,1975-2008[J]. Blood, 2013, 121(15):2996-3004.
|
| [19] |
PAPAEMANNUIL E, GERSTUNG M, MALCOVATI L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes[J]. Blood, 2013, 122(22):3616-3627.
|
| [20] |
BRUZZESE A, MARTINO E A, LABANCA C, et al. Therapy-related acute promyelocytic leukemia:case series and current insights[J]. Eur J Haematol, 2025, 114(1):195-198.
|
| [21] |
胡蓓莉, 王宙政, 王兆丰, 等. 弥漫大B细胞淋巴瘤治疗后继发急性早幼粒细胞白血病1例并文献复习[J]. 临床血液学杂志, 2015, 28(1):72-74.
|
| [22] |
余庭玉, 王利. 淋巴瘤治疗后继发急性白血病研究进展[J]. 临床血液学杂志, 2020, 33(9):664-669.
|
| [23] |
MCNERNEY M E, GODLEY L A, LE BEAU M M. Therapy-related myeloid neoplasms:when genetics and environment collide[J]. Nat Rev Cancer, 2017, 17(9):513-527.
|
| [24] |
RASHIDI A, FISHER S I. Therapy-related acute promyelocytic leukemia:a systematic review[J]. Med Oncol, 2013, 30(3):625.
|
| [25] |
WINER E S. Secondary acute myeloid leukemia:a primary challenge of diagnosis and treatment[J]. Hematol Oncol Clin North Am, 2020, 34(2):449-463.
|
